摘要
目的探讨依达拉奉治疗脑梗死的疗效,以及对患者血清金属基质蛋白酶9(MMP-9)和预后的影响。方法选取80例在我院确诊为脑梗死的患者作为观察对象,按随机表法分为观察组和对照组,两组各40例,对照组应用常规治疗,观察组在常规治疗基础上加用依达拉奉进行治疗,观察比较两组的疗效,以及两组治疗前后血清MMP-9的变化及预后。结果观察组基本治愈13例,显著进步12例,进步11例,无变化2例,恶化2例,死亡0例,总有效率为90.0%(36/40)。对照组基本治愈10例,显著进步11例,进步9例,无变化6例,恶化3例,死亡1例,总有效率为75.0%(30/40),两组疗效比较,差异无统计学意义(u=1.263,P=0.206)。治疗后两组血清MMP-9水平均较治疗前明显降低,但观察组较对照组降低更显著,差异有统计学意义(P<0.05)。结论依达拉奉对脑梗死患者疗效确切,降低与MMP-9,值得临床推广和应用。
Objective To investigate the impact of Edaravone on serum matrix metalloproteinase 9（MMP-9） and prognosis of patients with cerebral infarction.Methods 80 cases with cerebral infarction selected in the research were randomly divided into observation group and control group according to the random number table,40 cases in each group.The control group were treated with conventional therapy,while the observation group were given edaravone on the basis of conventional therapy.The efficacy and the serum MMP-9 and prognosis were compared before and after treatment between the two groups.Results There were no significant differences between the two groups（u=1.263,P=0.206）.After treatment,the content of serum MMP-9 reduced significantly,and especially the observation group decreased more significantly.The differences were significant（P0.05）.Conclusion The efficacy of Edaravone on the treatment of cerebral infarction patients was exact.It can significantly improve the prognosis of patients,probably related to the regulation of MMP-9.It is worthy of promotion and application in clinic.
出处
《内科》
2012年第2期117-119,共3页
Internal Medicine
